Johnson & Johnson, Talc
Digest more
Top News
Impacts
Next steps
Investopedia |
The company said Tuesday that a judge denied its plan to settle thousands of legal claims alleging that its talc products cause ovarian cancer, adding that it will now return to the tort system to li...
Reuters |
Johnson & Johnson has signaled that it will attempt to disqualify certain plaintiffs' lawyers and use other aggressive litigation tactics as it resumes defending tens of thousands of lawsuits allegin...
Seattle Times |
J&J said in a statement that it will not pursue an appeal, and instead will return to the civil law system “to litigate and defeat these meritless talc claims.”
Read more on News Digest
Mike Johnson, House Speaker
Digest more
Mike Johnson, GOP and Republican Rebellion
Digest more
Top News
Overview
Impacts
Wall Street Journal |
House Speaker Mike Johnson (R., La.) failed to tamp down a revolt from some rank-and-file Republicans trying to bypass his authority, in a tussle that included charges of political blackmail and a cra...
Washington Times |
House Speaker Mike Johnson on Tuesday canceled votes for the rest of the week after he failed to stop renegade Republicans from forcing a vote to restore proxy voting in the chamber.
Axios |
Even Republicans who did not sign on to Luna's discharge petition expressed frustration that Johnson is forcing them to choose between the non-citizen voting bill and the proxy voting rule.
Read more on News Digest
2h
Zacks Investment Research on MSNJohnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to ConsiderJohnson & Johnson (JNJ) closed the latest trading day at $155.36, indicating a +1.38% change from the previous session's end. The stock's change was more than the S&P 500's daily gain of 0.67%. On the other hand,
One big reason the Dow Jones Industrial Average slipped Tuesday had little to do with tariffs. Johnson & Johnson's stock tumbled 6.5% after a [bankruptcy judge dismissed](
Explore more
A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it liable in a whistleblower lawsuit for illegally promoting the HIV drugs Prezista and Intelence.
Johnson & Johnson announced it has completed its acquisition of Intra-Cellular Therapies. Intra-Cellular Therapies is now part of Johnson
Shares of Goldman Sachs and Johnson & Johnson are seeing positive growth Wednesday morning, sending the Dow Jones Industrial Average into positive territory. The Dow was most recently trading 123 points,
Two letter writers take issue with Sen. Ron Johnson's comments that federal judges are overstepping constitutional boundaries in blocking Trump moves.
Johnson & Johnson’s plan to settle thousands of talc-related lawsuits through bankruptcy was shot down in court.
Tesla stock rises after ending the first quarter down 36%, its worst first quarter on record, and Johnson & Johnson tumbles after its latest talc resolution is rejected by a judge.